HighPoint Advisor Group LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)

HighPoint Advisor Group LLC raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 229,367 shares of the biopharmaceutical company's stock after purchasing an additional 27,026 shares during the quarter. HighPoint Advisor Group LLC's holdings in Pfizer were worth $5,457,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Providence Capital Advisors LLC grew its position in Pfizer by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after acquiring an additional 409 shares in the last quarter. William B. Walkup & Associates Inc. grew its position in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after acquiring an additional 454 shares in the last quarter. Members Trust Co grew its position in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 467 shares in the last quarter. Sutton Place Investors LLC grew its position in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after acquiring an additional 472 shares in the last quarter. Finally, Bellevue Group AG grew its position in Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after acquiring an additional 485 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded down $0.05 on Thursday, reaching $25.32. The stock had a trading volume of 12,267,735 shares, compared to its average volume of 45,424,172. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The business's 50-day moving average price is $24.20 and its 200 day moving average price is $24.71. The stock has a market cap of $143.93 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.79%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Bank of America lifted their target price on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Morgan Stanley boosted their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.